Date: 2016-06-27
Type of information: Grant
Company: Emergent Biosolutions (USA - MD)
Investors: Biomedical Advanced Research and Development Authority (BARDA) (USA)
Amount: up to $21.9 million
Funding type: grant
Planned used: These funds will be used to develop and manufacture three cGMP lots of a Zika vaccine for use in a Phase 1 clinical trial. Using a base vaccine candidate provided by BARDA, the company will conduct technology transfer of process materials and information, process and analytical method development, execute small-scale production runs, and perform cGMP cell banking leading to cGMP manufacture of bulk drug substance and final drug product.
Others: * On June 27, 2016, Emergent BioSolutions announced that its Center for Innovation in Advanced Development and Manufacturing (CIADM) has received a task order from the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $21.9 million to develop and manufacture three cGMP lots of a Zika vaccine for use in a Phase 1 clinical trial. The task order consists of a 30-month base valued at $17.9 million and includes options that, if executed, will bring the total value to up to $21.9 million.
This Task Order Number HHSO10033003T under contract HHSO100201200004I is funded by BARDA, within the Office of the Assistant Secretary for Preparedness and Response in HHS.
Therapeutic area: Infectious diseases
